OPK Opko Health Inc.

1.21
-0.13  -10%
Previous Close 1.34
Open 1.28
Price To Book 0.5
Market Cap 810,492,514
Shares 669,828,524
Volume 13,553,258
Short Ratio
Av. Daily Volume 15,455,827
Stock charts supplied by TradingView

NewsSee all news

  1. OPKO Health Reports Interim Results for Two Ongoing RAYALDEE Studies

    Phase 4 Head-to-Head Study in Patients with Stage 3 or 4 Chronic Kidney Disease Phase 2 Trial in Patients with Stage 5 Chronic Kidney Disease on Dialysis MIAMI, March 25, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc.

  2. OPKO Health's BioReference Laboratories and City of Miami Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 24, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the City of Miami to provide coronavirus disease 2019

  3. OPKO Health's BioReference Laboratories and City of Detroit Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 23, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the City of Detroit to provide coronavirus disease 2019

  4. OPKO Health's BioReference Laboratories and State of New Jersey Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 20, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the State of New Jersey to provide coronavirus disease 2019

  5. OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 17, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the New York City Health and Hospital Corporation (NYC Health

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b top-line data March 21, 2019 met primary endpoint. Phase 3 trial planned.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial suspension announced January 31, 2019.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 initial open label data noted trial was well tolerated - March 25, 2020. Final top-line data 3Q 2020.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 data met primary endpoint - October 21, 2019.
Somatrogon (hGH-CTP)
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. OPKO Health Reports Interim Results for Two Ongoing RAYALDEE Studies

    Phase 4 Head-to-Head Study in Patients with Stage 3 or 4 Chronic Kidney Disease Phase 2 Trial in Patients with Stage 5 Chronic Kidney Disease on Dialysis MIAMI, March 25, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc.

  2. OPKO Health's BioReference Laboratories and City of Miami Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 24, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the City of Miami to provide coronavirus disease 2019

  3. OPKO Health's BioReference Laboratories and City of Detroit Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 23, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the City of Detroit to provide coronavirus disease 2019

  4. OPKO Health's BioReference Laboratories and State of New Jersey Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 20, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the State of New Jersey to provide coronavirus disease 2019

  5. OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 17, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration with the New York City Health and Hospital Corporation (NYC Health

  6. OPKO's BioReference Laboratories Offers Testing for Coronavirus Disease 2019 (COVID-19)

    ELMWOOD PARK, N.J., March 13, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for testing of coronavirus disease 2019 (COVID-19) from healthcare

  7. OPKO Health's BioReference Laboratories to Introduce Coronavirus Disease (COVID-19) Test

    ELMWOOD PARK, N.J., March 5, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced it will offer a test for the novel coronavirus (2019-nCoV), a contagious virus that

  8. OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial Results

    MIAMI, Feb. 26, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended December 31, 2019. Business Highlights Successful Phase 3

  9. OPKO Health to Report Fourth Quarter 2019 Financial Results on February 26, 2020

    MIAMI, Feb. 20, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended December 31, 2019, as well as provide guidance on expected revenues and

  10. Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert

    Harbert Repeatedly Demonstrates a Profound Lack of Understanding of Enzo's Business and Sector Falsely Asserts Enzo Has Failed to Make Substantial Changes Mischaracterizes True Nature of Dialogue Regarding its

  11. BioReference Laboratories Showcases 2019 Growth through the Addition of Cutting Edge Tests, Greater Access to Services, and Optimized Patient Experience

    Elmwood Park, NJ, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, Inc., and oncology, urology and women's health

  12. OPKO Health to Present at the 38th Annual J.P. Morgan Healthcare Conference

    MIAMI, Dec. 19, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) announced today that management will be participating in the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 at the Westin

  13. OPKO Health to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    MIAMI, Nov. 26, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced that Company management will be participating in the 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the

  14. Novitas Issues Final Local Coverage Determination for the 4Kscore® Test

    MIAMI, Nov. 15, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with

  15. OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results

    MIAMI, Nov. 05, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended September 30, 2019. Business Highlights Somatrogon meets

  16. BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic Disorders

    Elmwood Park, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women's health division, GenPath, today

  17. OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019

    MIAMI, Nov. 01, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report its operating and financial results for the three months ended September 30, 2019, as well as provide guidance on expected

  18. OPKO Health, Inc. Announces Pricing of its Offering of Common Stock

    MIAMI, Oct. 24, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ("OPKO Health" or the "Company") (NASDAQ:OPK) today announced the pricing of an underwritten public offering of 50 million shares of its common stock (the

  19. OPKO Health, Inc. Announces Proposed Offering of Common Stock

    MIAMI, Oct. 22, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ("OPKO Health" or the "Company") (NASDAQ:OPK) today announced that, subject to market and other conditions, it intends to offer and sell up to $100 million of

  20. OPKO Health Switches to Multichannel Veeva CRM to Drive More Effective Customer Engagement

    Veeva CRM empowers pharmaceutical field representatives with the right information they need to deliver a personalized customer experience Veeva Systems (NYSE:VEEV) today announced that OPKO Health (NASDAQ:OPK), a

  21. OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

    MIAMI, Aug. 29, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that the last patient has completed the final visit in the Company's pivotal Phase 3 study evaluating the safety and efficacy of